Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AXT 1003

Next Previous
X
Search
Drug Profile

AXT 1003

Alternative Names: AXT-1003

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Axter Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Enhancer of zeste homolog 2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma
  • Preclinical Prostate cancer; Solid tumours

Most Recent Events

  • 16 Jul 2024 Axter Therapeutics plans to initiate a phase I trial for Non-Hodgkin Lymphoma (Second-line therapy or greater) and Solid tumours (Late-stage disease, Metastatic disease) in China (PO) (NCT06484985)
  • 22 Feb 2024 Preclinical trials in Prostate cancer in China (PO) (Axter Therapeutics pipeline, February 2024)
  • 05 Sep 2023 Axter Therapeutics terminates a phase-I clinical trial in Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (PO) as there was an adjustment of the protocol and expansion of the indication population (NCT05965505)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top